Loren Data's SAM Daily™

FBO DAILY - FEDBIZOPPS ISSUE OF JULY 06, 2014 FBO #4607
MODIFICATION

99 -- Service contract TCR sequencing Adaptive Biotechnologies

Notice Date

7/4/2014
 

Notice Type

Modification/Amendment
 

NAICS

541711 — Research and Development in Biotechnology
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
 

ZIP Code

20852
 

Solicitation Number

N02RC42535-83
 

Archive Date

7/26/2014
 

Point of Contact

Gwennifer K. Epps, Phone: 240-276-5445, Terry Galloway, Phone: 240-276-5384
 

E-Mail Address

eppsg@mail.nih.gov, gallowaytl@mail.nih.gov
(eppsg@mail.nih.gov, gallowaytl@mail.nih.gov)
 

Small Business Set-Aside

N/A
 

Description

*** Amendment has been made to change the advertised procurement procedures of this original announcement from a simplified acquisition procedure to a combined synopsis/solicitation for commercial items. Des cription The National Cancer Institute (NCI), Center for Cancer Research (CCR), Surgery Branch (SB) plans to procure on a sole source basis a service contract for 40,000 input genomes, and 200,000 TCR sequences survey which includes a DNA Extraction Fee and domestic shipping and handling, from Adaptive Biotechnologies, 1551 Eastlake Ave E #200, Seattle, WA 98102. This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotes are being requested and a written solicitation will not be issued. The combined synopsis/ solicitation number remains the same: N02RC42535-83. This solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC 20) 05-72, (January 2014) Simplified Procedures for a Commercial Item. The Government contemplates only one award of a Firm-Fixed Price contract. The Associated North America Industry Classification Code (NAICS) 541711 and the Business Size Standard is 500. It has been determined there are no opportunities to acquire green products or services for this procurement. Only one award will be made as a result of this solicitation. The Surgery Branch of the National Cancer Institute has a dual function at the NIH. Investigators in the Branch are involved in the conduct of laboratory and clinical research aimed at improving the care, management, and outcome of patients with cancer. Important areas of laboratory research include tumor immunology, immunotherapy and gene therapy of solid tumors, epigenetic changes in pulmonary malignancies, tumor stem cells, and molecular changes in breast carcinogenesis. In these studies, an emphasis is placed on the translation of laboratory findings into the development of clinical protocols. Clinical efforts emphasize the development of new approaches to the immunotherapy of cancer, to the diagnostic and prognostic evaluation of solid tumors, as well as the development of innovative surgical and adjunctive approaches to the treatment of patients with primary and metastatic cancer. T cells express a T cell receptor (TCR) on the cell surface that determines their specificity. A TCR is created by selecting and splicing together a single V, D and J segment from a collection of available genomic segments. At the junctions between V-D and D-J segments, a varying number of nucleotides are deleted and a special enzyme inserts random nucleotides, creating a unique TCR. It is these inserted nucleotides that are responsible for the vast diversity found in the human TCR repertoire. T cell receptor immune-profiling can be used to monitor T cell responses to a given immune challenge even without the knowledge of the specific epitope targeted. NCI is particularly interested in performing TCR sequencing from T cell populations isolated from human tumor samples. In the tumors, T cells are exposed to tumor antigens, and the frequency of a specific TCR clonotype could be indicative of its ability to recognize the tumor. Thus, the study of the intratumoral T cell repertoire may lead to novel ways to rapidly identify and isolate TCRs that can be used to treat patients with cancer. The technology necessary to sequence the hyper variable region of the TCR involves a multiplex PCR with a mixture of primers targeting the rearranged variable and joining segments to capture receptor diversity. Differential hybridization kinetics can introduce significant amplification biases that alter the composition of sequence libraries and potentially biasing the data obtained. To identify and minimize such biases Adaptive Biotechnologies uses a synthetic immune receptor repertoire, which enables the computational removal residual bias after sequencing. Adaptive Biotechnologies has invented a patent-pending technology that utilizes advances in high-throughput sequencing and a state-of-the-art computer infrastructure to provide researchers in-depth analysis of the T-cell receptor repertoire. With this technology, scientists are able to identify the exact makeup of approximately 10-15 million unique TCRs in one individual, compared to previous techniques that could catalog only about 30,000. In addition to the qualifications of Adaptive to perform this service they provide their service at a highly competitive price. Finally, TCR deep sequencing is a relatively new and evolving technology and Adaptive Biotechnologies has pioneered this technology and made it commercially available. Adaptive Biotechnologies has 6+ years of a proven track record, including a growing list of clients, and their services have resulted in the publication of numerous articles in peer reviewed scientific journals, and has works in close contact with the Surgery Branch in providing state-of-the-art technology and superior serving. No other company provides the services provided by Adaptive Biotechnologies, including TCR sequencing and personalized analysis adapted to each project at such a competitive price. NCI has been working with Adaptive technologies and have performed some control experiments to test their technology, even with low starting cell number (<10,000), and have received accurate results back. Thus, the results provided by Adaptive Biotechnologies have proven to be reliable, and give NCI confidence to proceed using their technology. Finally, the service contract provided by Adaptive Biotechnologies will provide the necessary tools NCI needs to study the TCR repertoire of intratumoral T cell subsets and may help NCI identify and isolate tumor-specific T cell receptors. Adaptive Biotechnologies has exclusively in-licensed a patent family from the FHRCR called "A Method of Measuring Adaptive Immunity. This patent provides exclusive access to the proprietary sequencing technology developed by Harlan Robins and Chris Carlson at the FHCRC. Adaptive has an 11 step sample preparation methodology which goes way beyond competition to standardize the template (genetic material) that is loaded onto the sequencer. In addition, Adaptive has written seven propriety software programs that "clean the data" after it comes off the sequencer. These steps remove bias, correct errors, and have other quality control mechanisms built in. Thus based on this information Adaptive Biotechnologies is the only known source for this service. QUOTATIONS ARE DUE: July 11, 2014 at 11:00 am, EST. PROVISIONS AND CLAUSES INFORMATION: This solicitation incorporates one or more solicitation provisions/clauses by reference with the same force and effect as if they were given in full text. Upon request, the CO will make their full text available. The following provisions and clauses will be incorporated by reference: 52.212-1 Instruction to Offerors Commercial Items 52.212-2, Evaluation Commercial Items: The purchase order will be awarded to the Lowest Price Technically Acceptable (LPTA). The award will be made on the basis of the lowest evaluated price of quotations meeting or exceeding the acceptability standards for the requirements/technical specifications stated above. The technical evaluation will be a determination based on information furnished by the vendor. The Government is not responsible for locating or securing any information which is not identified in the proposal. The Government reserves the right to make an award without discussions. 52.212-3 Offerors Representations and Certifications Commercial Items (November 2013) WITH DUNS NUMBER ADDENDUM (52.204-6 (July 2013): 52.212-4 Contract Terms and Conditions Commercial Items, applies to this acquisition. 52.247-34 FOB Destination 52.212-5 Contract terms and Conditions Required to Implement Statutes or Executive Orders---Commercial Items (January 2014). The following additional FAR clauses cited in this clause are applicable: (b) The Contractor shall comply with the FAR clauses in this paragraph (b) that the Contracting Officer has indicated as being incorporated in this contract by reference to implement provisions of law or Executive orders applicable to acquisitions of commercial items: 52.203-13, Contractor Code of Business Ethics and Conduct 52.209-9, Updates of Publicly Available Information Regarding Responsibility Matters 52.219-4 Notice of Price Evaluation Preference for HUBZone Small Business Concerns 52.219-8 Utilization of Small Business Concerns 52.219-28 Post Award Small Business Program Representation 52.222-3, Convict Labor 52.222-26 Equal Opportunity 52.222-35 Equal Opportunity for Veterans 52.222-36 Affirmative Action for Workers with Disabilities 52.222-40 Notification of Employee Rights Under the National Labor Relations Act 52.222-37 Employment Reports on Veterans 52.223-18, Encouraging Contractor Policies to Ban Text Messaging while Driving 52.225-1 Buy American Act - Supplies 52.225-5 Trade Agreements 52.225-13 Restrictions on Certain Foreign Purchase 52.232-33 Payment by Electronic Funds Transfer System for awards Management 52.247-64, Preference for Privately-Owned U.S. Flag Commercial Vessels 52.246-2 Inspection of Supplies-Fixed Price Quotations must be received in the NCI-OA contracting office by 11:00 a.m. EST on July 11, 2014. Please refer to the solicitation number N02RC42535-83 on all correspondence. No collect calls will be accepted. Faxed or electronic mail quotations will NOT be accepted. OFFERORS: Offers must be submitted on an SF-1449 with a completed 52.212-3 Offeror Representations and Certifications-Commercial Items-with DUNS Number Addendum, signed by an authorized representative of the offeror OR provide a copy of the valid certification registrations of the offeror's Central Contractor Registration (CCR) and Online Representations and Certifications Applications (ORCA) through sam.gov. All questions shall be in writing and may be addressed to the aforementioned individual noted above by July 11, 2014. No collect calls will be accepted. In order to receive an award, contractor must be registered and have valid certification in the Central Contractor Registration (CCR) and the Online Representation and Certifications Applications (ORCA) through sam.gov.
 

Web Link

FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02RC42535-83/listing.html)
 

Place of Performance

Address: Building 10, Clinical Research Center, Bethesda, Maryland, 20814, United States

Zip Code: 20814
 

Record

SN03415495-W 20140706/140704233024-22bccd2dd71a84264c25c60f554455b6 (fbodaily.com)
 

Source

FedBizOpps Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |